[Angiotensin-I converting enzyme]. 1995

K Nakai, and T Syoh, and K Hiramori
Second Department of Internal Medicine, Iwate Medical University.

Angiotensin I-converting enzyme (ACE) converts the largely inactive decapeptide angiotensin I to the active octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that has long been suspected to play a role in the pathogenesis of hypertension and cardiovascular disease. The ACE gene spans 21 kilobases and consists of 26 exons, and two different mRNAs and endothelial and testicular ACE are transcribed from the ACE gene. Circulating ACE probably originates from proteolytic cleavage of the hydrophobic anchor and passive leakage of the membrane-bound enzyme. Normal serum ACE by spectrophotometric assay is very low (8.3-21.4 microliters/ml). The abnormally elevated ACE levels is indeed a diagnostic aid in sarcoidosis. The ACE gene has 287 base pair insertion/deletion polymorphism in intron 16. The ACE deletion polymorphism appears to be associated with increased risk for myocardial infarction in the Caucasian and Japanese population. Recently in multicenter clinical trials (SAVE), administration of inhibitors of ACE were shown to decrease cardiac events after myocardial infarction.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

K Nakai, and T Syoh, and K Hiramori
January 1989, Advances in experimental medicine and biology,
K Nakai, and T Syoh, and K Hiramori
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
K Nakai, and T Syoh, and K Hiramori
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
K Nakai, and T Syoh, and K Hiramori
February 1975, Circulation research,
K Nakai, and T Syoh, and K Hiramori
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
K Nakai, and T Syoh, and K Hiramori
April 1987, Laboratory investigation; a journal of technical methods and pathology,
K Nakai, and T Syoh, and K Hiramori
April 1977, Federation proceedings,
K Nakai, and T Syoh, and K Hiramori
January 2020, Frontiers in pharmacology,
K Nakai, and T Syoh, and K Hiramori
November 2004, Cellular and molecular life sciences : CMLS,
K Nakai, and T Syoh, and K Hiramori
February 1988, Human pathology,
Copied contents to your clipboard!